// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























4177 Abstracts

Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)

David Gandara - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Durvalumab

Dual targeting of CAR-NK cells to PD-L1 and ErbB2 facilitates specific elimination of cancer cells of solid tumor origin and overcomes immune escape by antigen loss

Jiri Eitler - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Characterization of HZ-G206: A potent and oral small molecule PD-L1 inhibitor

Yizhe WU - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata Patil - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Atezolizumab

Gene therapy with p19Arf and interferon-beta sensitizes cells to PD-1 checkpoint blockade and enhances antitumor immune responses in resistant mouse models

Ana Domingues - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Interferon Beta

Hydroxychloroquine synergizes with anti-PD-1 immune checkpoint blockade in squamous carcinoma of the head and neck

Avani Vyas - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Hydroxychloroquine

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer receiving immune check-point inhibitors – applicability and potential caveats

Line Nederby - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

A PD-L1 reporter cell line based on the immune checkpoint protein profiling of ATCC cell lines facilitates cancer immunotherapy drug screening

Hyeyoun Chang - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon

YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers

Narae Lee - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies

Tingting Zhong - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prevalence of PD-L1 expression among patients with recurrent and metastatic head and neck squamous cell carcinoma in Taiwan

Chia-Jui Yen - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Identifying genetic factors for resistance and response to immune checkpoint inhibitors (icis) in advanced non-small cell lung cancer (nsclc) patients using real-world data

Neeraj Singh - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenvironment

Byoung S Kwon - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

rhIL-4

PD-1 Inhibits Bystander T Cell Activation and Protects from Activation Induced Cell Death

Michael Sheng - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

rhIL-2

Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology

Sonia Dolfi - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon Gamma

Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors

Kevin Harrington - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)

Maura Gillison - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Oropharyngeal squamous cell carcinoma

Ipilimumab

Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti–PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial

Emiliano Calvo Aller - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Nivolumab

Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab

Khaled Tolba - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Atezolizumab

Novel digital image approach of multiplex immunofluorescence based PD-L1 expression enables the stratification of advanced NSCLC patients treated with durvalumab

Nicolas Brieu - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Durvalumab

Copyright © 2026. QuantiNova All rights reserved